Six CRC Breakthroughs

Colorectal cancer (CRC) care continues to evolve at a rapid pace with smarter biomarker strategies, organ-preserving approaches, and survivorship interventions that meaningfully change outcomes. So, what are the key breakthroughs driving these changes?

A Less Invasive Alternative for Rectal Cancer Treatment

For years, patients with rectal cancer have faced the prospect of total mesorectal excision, an effective but invasive surgery with significant risks and a lasting impact on quality of life.¹

A new approach combining chemoradiotherapy with transanal endoscopic microsurgery is showing promise as a safer, less invasive option.

For care teams, this highlights the importance of offering tailored treatment options that balance effectiveness with quality of life, empowering patients to make informed decisions about their care.

Transforming First-Line Treatment for BRAF V600E–Mutant mCRC

For patients with metastatic CRC (mCRC) and the BRAF V600E mutation, treatment options have historically been limited.² However, findings from the BREAKWATER trial are changing the game.

A combination of encorafenib, cetuximab, and mFOLFOX6 has shown significantly improved response rates and longer-lasting benefits compared with standard chemotherapy. These findings build on earlier success with encorafenib and cetuximab in previously treated patients.

A New Hope for Patients With Relapsed/Refractory mCRC

For those with relapsed or refractory mCRC, treatment options have been scarce—until now.³ The STELLAR-303 trial has introduced a groundbreaking combination of zanzalintinib and atezolizumab.

This combination has demonstrated meaningful survival benefits, especially for patients without liver metastases, and offers a chemotherapy-free treatment option that could improve quality of life for heavily pretreated patients.

For patients and care teams, these findings highlight a novel, effective treatment option that could provide much-needed hope for those facing advanced CRC.

Personalizing Treatment Decisions With ctDNA Testing

Could a simple blood test change how we treat CRC? Circulating tumor DNA (ctDNA) testing is proving it can.⁴

By detecting tiny amounts of tumor DNA in the blood, this tool helps identify patients at higher or lower risk of recurrence after surgery. For low-risk patients, this means less intensive chemotherapy, sparing them from unnecessary side effects and hospitalizations while maintaining strong outcomes. For high-risk patients, ctDNA testing highlights the need for new, more effective treatment options.

This innovative approach marks an important step toward improving quality of life and outcomes in CRC treatment.

Aspirin’s Potential Role in Reducing Recurrence

A well-known household name—aspirin—is showing promise as an affordable, low-risk option for certain patients with resected colon cancer and PIK3CA mutations.⁵ A recent trial revealed that adjuvant aspirin use may improve disease-free survival and reduce recurrence rates, offering a simple yet effective complement to traditional treatments.

While further research is needed, this trial highlights the importance of exploring innovative and accessible treatments to improve long-term outcomes.

The Power of Staying Active

A long-term study demonstrated that patients who participated in a structured exercise program after surgery and chemotherapy saw significantly better outcomes, including higher disease-free survival rates and potential improvements in overall survival.⁶

For care teams, this trial highlights the importance of encouraging physical activity as a key component of survivorship plans.

Each of these breakthroughs represents steps toward a more compassionate, patient-centered care approach. Navigators play a critical role in bringing these advances to life, helping patients understand their options and make decisions that align with their values and goals.

References

1. Serra-Aracil X, Pericay C, Cidoncha A, et al. Chemoradiotherapy and local excision vs total mesorectal excision in T2-T3ab, N0, M0 rectal cancer: the TAUTEM randomized clinical trial. JAMA Surg. 2025;160:783-793.
2. Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31:901-908.
3. Hecht JR, Park YS, Tabernero J, et al. Zanzalintinib plus atezolizu­mab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025;406:2360-2370.
4. Tie J, Wang Y, Loree JM, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nat Med. 2025;31:4291-4300.
5. Güller U, Hayoz S, Horber D, et al. Adjuvant aspirin treatment in PIK3CA-mutated colon cancer patients: the SAKK 41/13 prospective randomized placebo-controlled double-blind trial. Clin Cancer Res. 2025;31:3142-3149.
6. Courneya KS, Vardy JL, O’Callaghan CJ, et al. Structured exercise after adjuvant chemotherapy for colon cancer. N Engl J Med. 2025;393:13-25.